Chinese genetic firm Novogene sues US over military designation

What happened

Chinese genetic sequencing firm Novogene sued the Pentagon in a Washington federal court over its inclusion on the US list of companies allegedly aiding Beijing’s military. The designation bars direct Pentagon contracts and, starting in 2027, restricts purchases through third parties; Novogene says it is unlawful and harmful.

Confirmed

Global impact / market context

The case puts Novogene’s access to US government-related sales at issue: if the designation remains, Pentagon purchases through third parties will also be restricted from 2027. A court challenge could change that outlook, while the company says the listing has already caused economic and reputational harm.

Analyst inference

The article describes a broader pattern of Chinese firms challenging Pentagon designations, including Alibaba, which recently won a preliminary injunction against denial of Pentagon contracts. That ruling shows litigation can affect contract access, but it does not establish the outcome of Novogene’s separate case.

Confirmed

What to watch

1. Watch for court decisions in Novogene’s case; a ruling on the designation could shape whether it remains eligible for direct Pentagon contracts and future purchases through third parties. Analyst inference
2. Track whether the Pentagon responds to the lawsuit and whether the court grants any temporary relief, which could alter restrictions before the 2027 third-party purchasing limits begin. Analyst inference
3. Novogene says its US unit employs about 180 people and alleges serious economic and reputational harm; the article gives no financial estimate of those effects. Confirmed

Evidence

• Original source link unavailable